← Back to Search

PET/CT Imaging for Heart Function in Lung Cancer

N/A
Recruiting
Led By Yevgeniy Vinogradskiy
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 months after radiotherapy
Awards & highlights
No Placebo-Only Group

Summary

This trial studies if PET/CT scans can help detect changes in heart function due to radiation therapy in lung cancer patients.

Who is the study for?
This trial is for adults with pathologically confirmed lung cancer who are about to undergo radiation therapy and have a life expectancy of at least 3 months. They must consent to the study's procedures, be available throughout, and receive a heart dose of radiation estimated at 5 Gy or more. It excludes those on palliative radiation doses or with contraindications for FDG PET-CT scans.
What is being tested?
The EUCLID Trial is testing the use of PET/CT imaging to detect potential cardiac damage from radiation treatment in lung cancer patients. The goal is to monitor heart function before, during, and after radiotherapy using this imaging technique which can highlight inflammation and tissue viability.
What are the potential side effects?
Since this trial involves diagnostic imaging rather than medication, side effects are minimal but may include discomfort from lying still during the scan or reactions related to contrast agents used in PET/CT such as allergic reactions or metallic taste.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 months after radiotherapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 months after radiotherapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in mean standardized uptake value (SUV) changes in the heart
Secondary study objectives
Ability of pre- to post-radiotherapy SUV changes in the heart
Cardiac related death
Cardiac toxicity
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (sarcoidosis FDG PET-CT)Experimental Treatment4 Interventions
Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2011
Completed Phase 2
~2200
Computed Tomography
2017
Completed Phase 2
~2740

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
462 Previous Clinical Trials
175,518 Total Patients Enrolled
Yevgeniy VinogradskiyPrincipal InvestigatorThomas Jefferson University

Media Library

Diagnostic (sarcoidosis FDG PET-CT) Clinical Trial Eligibility Overview. Trial Name: NCT05775939 — N/A
Esophageal Cancer Research Study Groups: Diagnostic (sarcoidosis FDG PET-CT)
Esophageal Cancer Clinical Trial 2023: Diagnostic (sarcoidosis FDG PET-CT) Highlights & Side Effects. Trial Name: NCT05775939 — N/A
Diagnostic (sarcoidosis FDG PET-CT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05775939 — N/A
~7 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top